- Home
- MLYS
as 03-25-2025 2:32pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 893.0M | IPO Year: | 2023 |
| Target Price: | $27.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $18.38 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | MLYS | Director | Mar 13 '25 | Buy | $13.50 | 1,296,296 | $17,499,996.00 | 4,280,051 | |
| AKKARAJU SRINIVAS | MLYS | Director | Mar 13 '25 | Buy | $13.50 | 600,000 | $8,100,000.00 | 5,674,916 | |
| Congleton Jon | MLYS | Chief Executive Officer | Jan 13 '25 | Sell | $9.06 | 18,333 | $166,082.31 | 877,608 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Jan 13 '25 | Sell | $9.36 | 10,757 | $97,863.90 | 226,197 |
Latest Mineralys Therapeutics Inc. News
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Insider Monkey
7 days ago
Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?
GlobeNewswire
8 days ago
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
MT Newswires
8 days ago
Mineralys Therapeutics Insider Bought Shares Worth $8,100,000, According to a Recent SEC Filing
GlobeNewswire
9 days ago
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
MT Newswires
14 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT Newswires
14 days ago
Mineralys Therapeutics Prices $175 Million Share Offering
GlobeNewswire
14 days ago
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
Compare MLYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.